Wolverine Asset Management LLC Sells 800 Shares of Quest Diagnostics Incorporated (NYSE:DGX)

Wolverine Asset Management LLC trimmed its position in shares of Quest Diagnostics Incorporated (NYSE:DGX) by 14.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,787 shares of the medical research company’s stock after selling 800 shares during the period. Wolverine Asset Management LLC’s holdings in Quest Diagnostics were worth $743,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Rothschild Investment LLC bought a new stake in shares of Quest Diagnostics in the 2nd quarter worth approximately $26,000. Innealta Capital LLC bought a new stake in shares of Quest Diagnostics during the 2nd quarter valued at about $31,000. Larson Financial Group LLC increased its position in shares of Quest Diagnostics by 77.5% during the second quarter. Larson Financial Group LLC now owns 229 shares of the medical research company’s stock valued at $31,000 after buying an additional 100 shares during the period. TruNorth Capital Management LLC bought a new position in Quest Diagnostics in the second quarter worth about $33,000. Finally, EdgeRock Capital LLC bought a new stake in Quest Diagnostics during the 2nd quarter valued at approximately $35,000. 88.06% of the stock is currently owned by hedge funds and other institutional investors.

Quest Diagnostics Stock Performance

Shares of DGX opened at $160.55 on Thursday. The company has a market cap of $17.92 billion, a price-to-earnings ratio of 21.58, a P/E/G ratio of 2.79 and a beta of 0.89. The business’s fifty day simple moving average is $153.69 and its two-hundred day simple moving average is $147.10. Quest Diagnostics Incorporated has a 12 month low of $123.04 and a 12 month high of $162.59. The company has a current ratio of 1.25, a quick ratio of 1.17 and a debt-to-equity ratio of 0.83.

Quest Diagnostics (NYSE:DGX) last released its quarterly earnings data on Tuesday, October 22nd. The medical research company reported $2.30 EPS for the quarter, topping the consensus estimate of $2.26 by $0.04. The company had revenue of $2.49 billion during the quarter, compared to the consensus estimate of $2.43 billion. Quest Diagnostics had a return on equity of 15.25% and a net margin of 8.82%. Quest Diagnostics’s revenue for the quarter was up 8.5% on a year-over-year basis. During the same period last year, the company earned $2.22 EPS. Research analysts anticipate that Quest Diagnostics Incorporated will post 8.9 earnings per share for the current fiscal year.

Quest Diagnostics Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, January 29th. Shareholders of record on Tuesday, January 14th will be given a $0.75 dividend. This represents a $3.00 dividend on an annualized basis and a yield of 1.87%. Quest Diagnostics’s dividend payout ratio (DPR) is presently 40.32%.

Insiders Place Their Bets

In other news, CAO Michael J. Deppe sold 18,755 shares of the stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $154.05, for a total transaction of $2,889,207.75. Following the transaction, the chief accounting officer now directly owns 34,941 shares of the company’s stock, valued at $5,382,661.05. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other news, SVP Karthik Kuppusamy sold 1,775 shares of the company’s stock in a transaction dated Monday, October 28th. The shares were sold at an average price of $156.92, for a total transaction of $278,533.00. Following the completion of the sale, the senior vice president now owns 9,734 shares of the company’s stock, valued at $1,527,459.28. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CAO Michael J. Deppe sold 18,755 shares of the stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $154.05, for a total transaction of $2,889,207.75. Following the completion of the transaction, the chief accounting officer now owns 34,941 shares in the company, valued at $5,382,661.05. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 22,520 shares of company stock valued at $3,472,728. Company insiders own 0.79% of the company’s stock.

Analyst Upgrades and Downgrades

DGX has been the subject of a number of research analyst reports. Mizuho raised their target price on Quest Diagnostics from $160.00 to $174.00 and gave the company an “outperform” rating in a research note on Thursday, October 24th. UBS Group upped their target price on shares of Quest Diagnostics from $165.00 to $166.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 23rd. Piper Sandler lifted their price target on shares of Quest Diagnostics from $150.00 to $165.00 and gave the company a “neutral” rating in a research report on Monday, October 28th. Baird R W upgraded shares of Quest Diagnostics from a “hold” rating to a “strong-buy” rating in a report on Wednesday, October 23rd. Finally, Evercore ISI began coverage on shares of Quest Diagnostics in a research note on Wednesday, August 28th. They set an “in-line” rating and a $165.00 target price for the company. Nine research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $164.58.

Quest Diagnostics Profile

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.